- Home
- INSM vs JKHY Comparison
INSM vs JKHY Comparison
Compare INSM & JKHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- JKHY
- Stock Information
- Founded
- INSM 1988
- JKHY 1976
- Country
- INSM United States
- JKHY United States
- Employees
- INSM N/A
- JKHY N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- JKHY Retail: Computer Software & Peripheral Equipment
- Sector
- INSM Health Care
- JKHY Technology
- Exchange
- INSM Nasdaq
- JKHY Nasdaq
- Market Cap
- INSM 12.6B
- JKHY 12.1B
- IPO Year
- INSM 2000
- JKHY N/A
- Fundamental
- Price
- INSM $69.73
- JKHY $181.17
- Analyst Decision
- INSM Strong Buy
- JKHY Hold
- Analyst Count
- INSM 17
- JKHY 9
- Target Price
- INSM $95.93
- JKHY $184.22
- AVG Volume (30 Days)
- INSM 2.3M
- JKHY 756.7K
- Earning Date
- INSM 05-08-2025
- JKHY 05-06-2025
- Dividend Yield
- INSM N/A
- JKHY 1.28%
- EPS Growth
- INSM N/A
- JKHY 13.10
- EPS
- INSM N/A
- JKHY 5.87
- Revenue
- INSM $381,030,000.00
- JKHY $2,319,828,000.00
- Revenue This Year
- INSM $29.15
- JKHY $8.37
- Revenue Next Year
- INSM $115.02
- JKHY $6.75
- P/E Ratio
- INSM N/A
- JKHY $30.86
- Revenue Growth
- INSM 20.77
- JKHY 5.92
- 52 Week Low
- INSM $53.69
- JKHY $157.00
- 52 Week High
- INSM $84.91
- JKHY $196.00
- Technical
- Relative Strength Index (RSI)
- INSM 53.15
- JKHY 53.98
- Support Level
- INSM $65.56
- JKHY $177.88
- Resistance Level
- INSM $68.74
- JKHY $185.19
- Average True Range (ATR)
- INSM 2.41
- JKHY 2.94
- MACD
- INSM 0.42
- JKHY -0.14
- Stochastic Oscillator
- INSM 76.91
- JKHY 47.08
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing for us banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.